Theseus Pharmaceuticals Inc (NASDAQ:THRX) Director Purchases $89,335.00 in Stock

Theseus Pharmaceuticals Inc (NASDAQ:THRX) Director Carl L. Gordon purchased 8,500 shares of the company’s stock in a transaction dated Tuesday, January 11th. The shares were acquired at an average price of $10.51 per share, for a total transaction of $89,335.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of THRX stock opened at $11.73 on Friday. Theseus Pharmaceuticals Inc has a one year low of $8.65 and a one year high of $24.54. The company’s fifty day moving average price is $13.52.

Theseus Pharmaceuticals (NASDAQ:THRX) last announced its quarterly earnings data on Monday, November 15th. The company reported ($5.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($4.93). On average, analysts anticipate that Theseus Pharmaceuticals Inc will post -1.72 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on THRX shares. Wedbush started coverage on shares of Theseus Pharmaceuticals in a research note on Monday, November 1st. They set an “outperform” rating and a $24.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Theseus Pharmaceuticals in a research note on Monday, November 1st. They set an “overweight” rating and a $25.00 price target on the stock. SVB Leerink started coverage on shares of Theseus Pharmaceuticals in a research note on Monday, November 1st. They set an “outperform” rating and a $28.00 price target on the stock. Finally, Jefferies Financial Group started coverage on shares of Theseus Pharmaceuticals in a research note on Monday, November 1st. They set a “buy” rating and a $23.00 price target on the stock.

Theseus Pharmaceuticals Company Profile

Theseus Pharmaceuticals Inc is a biopharmaceutical company. It focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company’s principal product candidate includes THE-630. Theseus Pharmaceuticals Inc is based in CAMBRIDGE, Mass.

Read More: What sectors are represented in the Nikkei Index?

Receive News & Ratings for Theseus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theseus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.